October 24, 2016 04:05 PM EDT
Pharma

FDA clears Glob­al Blood Ther­a­peu­tics to fo­cus on key bio­mark­er in piv­otal sick­le cell tri­al

John Carroll

Editor & Founder

Just days af­ter flesh­ing out its lat­est set of pos­i­tive da­ta from a tiny study of GBT440 for sick­le cell dis­ease, Glob­al Blood Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

A look at biotech's year of the megaround

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

A service from the Financial Times